Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR
- None.
- None.
Insights
Lawsuit alleges manufacturing-control failures and misleading statements; outcome and liability remain unproven.
Jasper Therapeutics faces a securities class action alleging violations of §§10(b) and 20(a) and Rule 10b-5 tied to its third-party manufacturing controls and related public statements during the
The factual core is that vendors allegedly failed to follow applicable rules and that those failures purportedly put clinical trials at risk, which the complaint says made prior public statements false or misleading. Those are procedural allegations; the complaint does not state any final adjudication, settlement, or regulatory finding in favor of plaintiffs.
Watch the court docket and milestones such as lead plaintiff appointment, the defendants’ motion to dismiss, and any disclosure corrections or settlements; calendar the
Securities suit introduces legal and disclosure risk; financial impact is currently indeterminate.
The complaint ties alleged misstatements to operational controls over third-party manufacturers, claiming those issues put trials at risk and misstated public information. The release encourages shareholder participation but provides no quantitative loss figures or corporate response.
Key dependencies include whether the company issues corrective disclosures, the court’s response to pleading-stage motions, and any announced settlements or regulatory findings. Monitor docket activity and any formal restatements or risk disclosures over the next several quarters to assess material financial effect.
LOS ANGELES, Nov. 11, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. ("Jasper" or "the Company") (NASDAQ: JSPR ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of JSPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: November 30, 2023 to July 3, 2025
DEADLINE: November 18, 2025
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Jasper's controls over third-party manufacturing was insufficient to ensure its vendors followed all applicable rules and regulations. The Company's clinical trials were placed at risk due to problems with its manufacturing partners. Based on these facts, Jasper's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
NEXT STEPS FOR SHAREHOLDERS : Once you register as a shareholder who purchased shares during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. There is no cost or obligation to you to participate in this case.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: David@djslawllp.com
View original content:https://www.prnewswire.com/news-releases/jasper-therapeutics-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--jspr-302610957.html
SOURCE DJS Law Group LLP
